nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Rectal tenesmus—Octreotide—thymus cancer	0.0412	0.0412	CcSEcCtD
Gadoversetamide—Proctalgia—Octreotide—thymus cancer	0.0327	0.0327	CcSEcCtD
Gadoversetamide—Rectal disorder—Octreotide—thymus cancer	0.0313	0.0313	CcSEcCtD
Gadoversetamide—Creatine phosphokinase increased—Octreotide—thymus cancer	0.0292	0.0292	CcSEcCtD
Gadoversetamide—Anorectal disorder—Octreotide—thymus cancer	0.0292	0.0292	CcSEcCtD
Gadoversetamide—Anorectal discomfort—Octreotide—thymus cancer	0.0281	0.0281	CcSEcCtD
Gadoversetamide—Local reaction—Octreotide—thymus cancer	0.0277	0.0277	CcSEcCtD
Gadoversetamide—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.0223	0.0223	CcSEcCtD
Gadoversetamide—Burning sensation—Octreotide—thymus cancer	0.0221	0.0221	CcSEcCtD
Gadoversetamide—Metrorrhagia—Octreotide—thymus cancer	0.0215	0.0215	CcSEcCtD
Gadoversetamide—Numbness—Octreotide—thymus cancer	0.0185	0.0185	CcSEcCtD
Gadoversetamide—Sensory loss—Octreotide—thymus cancer	0.0177	0.0177	CcSEcCtD
Gadoversetamide—Breast pain—Octreotide—thymus cancer	0.0176	0.0176	CcSEcCtD
Gadoversetamide—Herpes simplex—Octreotide—thymus cancer	0.0167	0.0167	CcSEcCtD
Gadoversetamide—Injection site reaction—Octreotide—thymus cancer	0.0153	0.0153	CcSEcCtD
Gadoversetamide—Eructation—Octreotide—thymus cancer	0.0151	0.0151	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Octreotide—thymus cancer	0.0141	0.0141	CcSEcCtD
Gadoversetamide—Sleep disorder—Octreotide—thymus cancer	0.0129	0.0129	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Octreotide—thymus cancer	0.0129	0.0129	CcSEcCtD
Gadoversetamide—Nasal congestion—Octreotide—thymus cancer	0.0122	0.0122	CcSEcCtD
Gadoversetamide—Injury—Octreotide—thymus cancer	0.0121	0.0121	CcSEcCtD
Gadoversetamide—Amnesia—Octreotide—thymus cancer	0.0119	0.0119	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Octreotide—thymus cancer	0.0114	0.0114	CcSEcCtD
Gadoversetamide—Dry skin—Octreotide—thymus cancer	0.0102	0.0102	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Octreotide—thymus cancer	0.00997	0.00997	CcSEcCtD
Gadoversetamide—Muscular weakness—Octreotide—thymus cancer	0.00983	0.00983	CcSEcCtD
Gadoversetamide—Influenza—Octreotide—thymus cancer	0.00963	0.00963	CcSEcCtD
Gadoversetamide—Asthma—Octreotide—thymus cancer	0.00963	0.00963	CcSEcCtD
Gadoversetamide—Bronchospasm—Octreotide—thymus cancer	0.00948	0.00948	CcSEcCtD
Gadoversetamide—Sweating increased—Octreotide—thymus cancer	0.00938	0.00938	CcSEcCtD
Gadoversetamide—Dysuria—Octreotide—thymus cancer	0.00901	0.00901	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Octreotide—thymus cancer	0.00869	0.00869	CcSEcCtD
Gadoversetamide—Pneumonia—Octreotide—thymus cancer	0.00864	0.00864	CcSEcCtD
Gadoversetamide—Urinary tract infection—Octreotide—thymus cancer	0.00835	0.00835	CcSEcCtD
Gadoversetamide—Conjunctivitis—Octreotide—thymus cancer	0.00835	0.00835	CcSEcCtD
Gadoversetamide—Haematuria—Octreotide—thymus cancer	0.00819	0.00819	CcSEcCtD
Gadoversetamide—Epistaxis—Octreotide—thymus cancer	0.0081	0.0081	CcSEcCtD
Gadoversetamide—Sinusitis—Octreotide—thymus cancer	0.00806	0.00806	CcSEcCtD
Gadoversetamide—Rhinitis—Octreotide—thymus cancer	0.00773	0.00773	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Octreotide—thymus cancer	0.00767	0.00767	CcSEcCtD
Gadoversetamide—Pharyngitis—Octreotide—thymus cancer	0.00765	0.00765	CcSEcCtD
Gadoversetamide—Oedema peripheral—Octreotide—thymus cancer	0.0076	0.0076	CcSEcCtD
Gadoversetamide—Tinnitus—Octreotide—thymus cancer	0.00719	0.00719	CcSEcCtD
Gadoversetamide—Flushing—Octreotide—thymus cancer	0.00716	0.00716	CcSEcCtD
Gadoversetamide—Cardiac disorder—Octreotide—thymus cancer	0.00716	0.00716	CcSEcCtD
Gadoversetamide—Immune system disorder—Octreotide—thymus cancer	0.00696	0.00696	CcSEcCtD
Gadoversetamide—Arrhythmia—Octreotide—thymus cancer	0.00689	0.00689	CcSEcCtD
Gadoversetamide—Mental disorder—Octreotide—thymus cancer	0.00676	0.00676	CcSEcCtD
Gadoversetamide—Malnutrition—Octreotide—thymus cancer	0.00671	0.00671	CcSEcCtD
Gadoversetamide—Erythema—Octreotide—thymus cancer	0.00671	0.00671	CcSEcCtD
Gadoversetamide—Flatulence—Octreotide—thymus cancer	0.00661	0.00661	CcSEcCtD
Gadoversetamide—Tension—Octreotide—thymus cancer	0.00659	0.00659	CcSEcCtD
Gadoversetamide—Nervousness—Octreotide—thymus cancer	0.00652	0.00652	CcSEcCtD
Gadoversetamide—Back pain—Octreotide—thymus cancer	0.00649	0.00649	CcSEcCtD
Gadoversetamide—Muscle spasms—Octreotide—thymus cancer	0.00645	0.00645	CcSEcCtD
Gadoversetamide—Vision blurred—Octreotide—thymus cancer	0.00633	0.00633	CcSEcCtD
Gadoversetamide—Tremor—Octreotide—thymus cancer	0.00629	0.00629	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Octreotide—thymus cancer	0.00623	0.00623	CcSEcCtD
Gadoversetamide—Agitation—Octreotide—thymus cancer	0.00617	0.00617	CcSEcCtD
Gadoversetamide—Malaise—Octreotide—thymus cancer	0.00605	0.00605	CcSEcCtD
Gadoversetamide—Vertigo—Octreotide—thymus cancer	0.00603	0.00603	CcSEcCtD
Gadoversetamide—Syncope—Octreotide—thymus cancer	0.00602	0.00602	CcSEcCtD
Gadoversetamide—Palpitations—Octreotide—thymus cancer	0.00593	0.00593	CcSEcCtD
Gadoversetamide—Loss of consciousness—Octreotide—thymus cancer	0.0059	0.0059	CcSEcCtD
Gadoversetamide—Cough—Octreotide—thymus cancer	0.00586	0.00586	CcSEcCtD
Gadoversetamide—Convulsion—Octreotide—thymus cancer	0.00582	0.00582	CcSEcCtD
Gadoversetamide—Hypertension—Octreotide—thymus cancer	0.0058	0.0058	CcSEcCtD
Gadoversetamide—Myalgia—Octreotide—thymus cancer	0.00571	0.00571	CcSEcCtD
Gadoversetamide—Chest pain—Octreotide—thymus cancer	0.00571	0.00571	CcSEcCtD
Gadoversetamide—Arthralgia—Octreotide—thymus cancer	0.00571	0.00571	CcSEcCtD
Gadoversetamide—Anxiety—Octreotide—thymus cancer	0.00569	0.00569	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00568	0.00568	CcSEcCtD
Gadoversetamide—Discomfort—Octreotide—thymus cancer	0.00565	0.00565	CcSEcCtD
Gadoversetamide—Dry mouth—Octreotide—thymus cancer	0.00559	0.00559	CcSEcCtD
Gadoversetamide—Oedema—Octreotide—thymus cancer	0.00548	0.00548	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Octreotide—thymus cancer	0.00548	0.00548	CcSEcCtD
Gadoversetamide—Shock—Octreotide—thymus cancer	0.00539	0.00539	CcSEcCtD
Gadoversetamide—Nervous system disorder—Octreotide—thymus cancer	0.00537	0.00537	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Octreotide—thymus cancer	0.00536	0.00536	CcSEcCtD
Gadoversetamide—Tachycardia—Octreotide—thymus cancer	0.00535	0.00535	CcSEcCtD
Gadoversetamide—Skin disorder—Octreotide—thymus cancer	0.00532	0.00532	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Octreotide—thymus cancer	0.0053	0.0053	CcSEcCtD
Gadoversetamide—Anorexia—Octreotide—thymus cancer	0.00522	0.00522	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00499	0.00499	CcSEcCtD
Gadoversetamide—Insomnia—Octreotide—thymus cancer	0.00495	0.00495	CcSEcCtD
Gadoversetamide—Paraesthesia—Octreotide—thymus cancer	0.00492	0.00492	CcSEcCtD
Gadoversetamide—Dyspnoea—Octreotide—thymus cancer	0.00488	0.00488	CcSEcCtD
Gadoversetamide—Somnolence—Octreotide—thymus cancer	0.00487	0.00487	CcSEcCtD
Gadoversetamide—Dyspepsia—Octreotide—thymus cancer	0.00482	0.00482	CcSEcCtD
Gadoversetamide—Decreased appetite—Octreotide—thymus cancer	0.00476	0.00476	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Octreotide—thymus cancer	0.00473	0.00473	CcSEcCtD
Gadoversetamide—Fatigue—Octreotide—thymus cancer	0.00472	0.00472	CcSEcCtD
Gadoversetamide—Constipation—Octreotide—thymus cancer	0.00468	0.00468	CcSEcCtD
Gadoversetamide—Pain—Octreotide—thymus cancer	0.00468	0.00468	CcSEcCtD
Gadoversetamide—Feeling abnormal—Octreotide—thymus cancer	0.00451	0.00451	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Octreotide—thymus cancer	0.00448	0.00448	CcSEcCtD
Gadoversetamide—Urticaria—Octreotide—thymus cancer	0.00435	0.00435	CcSEcCtD
Gadoversetamide—Abdominal pain—Octreotide—thymus cancer	0.00433	0.00433	CcSEcCtD
Gadoversetamide—Body temperature increased—Octreotide—thymus cancer	0.00433	0.00433	CcSEcCtD
Gadoversetamide—Hypersensitivity—Octreotide—thymus cancer	0.00404	0.00404	CcSEcCtD
Gadoversetamide—Asthenia—Octreotide—thymus cancer	0.00393	0.00393	CcSEcCtD
Gadoversetamide—Pruritus—Octreotide—thymus cancer	0.00388	0.00388	CcSEcCtD
Gadoversetamide—Diarrhoea—Octreotide—thymus cancer	0.00375	0.00375	CcSEcCtD
Gadoversetamide—Dizziness—Octreotide—thymus cancer	0.00362	0.00362	CcSEcCtD
Gadoversetamide—Vomiting—Octreotide—thymus cancer	0.00348	0.00348	CcSEcCtD
Gadoversetamide—Rash—Octreotide—thymus cancer	0.00345	0.00345	CcSEcCtD
Gadoversetamide—Dermatitis—Octreotide—thymus cancer	0.00345	0.00345	CcSEcCtD
Gadoversetamide—Headache—Octreotide—thymus cancer	0.00343	0.00343	CcSEcCtD
Gadoversetamide—Nausea—Octreotide—thymus cancer	0.00325	0.00325	CcSEcCtD
